Ernamín at the 55th Congress of the Spanish Society of Nephrology

Stand Ernamín

Ernamín at the 55th Congress of the Spanish Society of Nephrology

From October 16–18, the 55th edition of the Congress of the Spanish Society of Nephrology (SEN) took place in Oviedo. For the first time, and following the launch of Ernamín, ERN Laboratories participated as a collaborator in the event, with a stand in the commercial exhibition area and by organizing a technical forum featuring high-level speakers.

The forum, titled “Use of Ketoanalogues for the Management of CKD in Spain: A New Reality”, brought together over one hundred nephrology professionals. Dr. Juan-Jesús Carrero, researcher at the Karolinska Institute in Sweden, and Dr. Pablo Molina, Head of the Nephrology Department at Hospital La Fe (València), presented evidence on low-protein diets in advanced CKD, the use of amino acid ketoanalogues in these patients, and the results of the ADHERENCE study. The forum was moderated by Dr. Huarte, Head of the Nephrology Department at Hospital San Millán-San Pedro de Logroño (La Rioja).

55th Congress of the Spanish Society of Nephrology

The ADHERENCE study is the first randomized clinical trial conducted with ketoanalogues in Spain, and its results, which reinforce existing evidence on the benefits of ketoanalogues, will be published soon in the journal Nefrología.

Ernamín is the only product available on the Spanish market (since last June) that contains a combination of essential amino acids and ketoanalogues, making it a unique nutritional tool for the dietary management of advanced CKD. Together with a very low-protein diet, Ernamín helps preserve kidney function, improves nutritional status, and delays the need for dialysis.

noticias relacionadas

barberà

Laboratorios ERN signs a collaboration agreement with Lupin Limited and launches a new medicine in Spain for the treatment of asthma and COPD

With more than 80 years of history, the laboratory founded in Barcelona continues to advance its sustainable growth strategy through alliances with leading international partners. Laboratorios ERN is taking a decisive step in strengthening its respiratory portfolio with the launch in Spain of Luforbec® (beclometasone / formoterol), 100/6, a fixed-dose combination in a pressurised metered-dose […]

Read more

Laboratorios ERN and Ercros, beneficiaries of CDTI funding for the development of the ANTISALINA project

Laboratorios ERN and Ercros are beneficiaries of public funding awarded under the National Cooperative R&D Programme of the Centre for the Development of Technology and Innovation (CDTI). Thanks to this funding, both companies are jointly advancing the ANTISALINA project, aimed at developing new innovative solutions in the field of research and experimental development. At Laboratorios […]

Read more
imagen logos

Launch of Intravenous Fosfomycin Commercialization in the United States

The commercialization of intravenous fosfomycin has begun in the United States. This hospital-use antibiotic is a key treatment for complicated urinary tract infections and is being introduced through a strategic agreement between LABORATORIOS ERN and the pharmaceutical company Meitheal Pharmaceuticals, a specialist in the commercialization of generic and biologic injectable products. Intravenous fosfomycin was approved […]

Read more

Laboratorios ERN joins the Fundación Empresa y Clima (FEC) as a Silver member

We are proud to announce that Laboratorios ERN has officially joined the Fundación Empresa y Clima (FEC) as a Silver member, reinforcing our commitment to climate action and global sustainability. This alliance allows us to become part of a business community committed to the transition toward a low-carbon economy, alongside other companies that share the […]

Read more

ERN Laboratories supports research into pediatric rare diseases at Sant Joan de Déu Hospital in Barcelona.

During 2026, ERN Laboratories will allocate €1 for each unit sold of Astenolit Infantil, a nutritional supplement designed to support children’s energy levels and immune defenses, to benefit pediatric rare disease research at Sant Joan de Déu. This initiative is part of ERN Laboratories’ longstanding commitment to pediatrics and child health, supporting projects that contribute […]

Read more